Literature DB >> 33947268

Considerations for Increasing Racial, Ethnic, Gender, and Sexual Diversity in HIV Cure-Related Research with Analytical Treatment Interruptions: A Qualitative Inquiry.

Karine Dubé1, John Kanazawa1, Chadwick Campbell2,3, Cheriko A Boone4, Allysha C Maragh-Bass5, Danielle M Campbell6, Moisés Agosto-Rosario7, Jamila K Stockman8, Dázon Dixon Diallo9, Tonia Poteat10, Mallory Johnson2, Parya Saberi2, John A Sauceda2.   

Abstract

Despite disproportionate incidence and prevalence of HIV among transgender individuals, cisgender women, and racial and ethnic minority groups, all remain underrepresented in HIV cure research. As HIV cure trials are scaled up, there is emerging research on ways to mitigate risks of HIV acquisition for sexual partners of analytical treatment interruption (ATI) trial participants. As such, it is imperative that HIV cure researchers consider the implications of implementing ATIs in populations that are disproportionately affected by HIV, but largely underrepresented in trials to date. In this qualitative study, we sought to derive triangulated perspectives on the social and ethical implications regarding ATIs and partner protection strategies during ATIs among under-represented populations. We conducted 21 in-depth interviews with 5 types of informants: bioethicists, community members [people living with HIV (PLWH) and their advocates], biomedical HIV cure researchers, sociobehavioral scientists, and HIV care providers. We analyzed the data using conventional content analysis and reduced the data to important considerations for implementing ATI trials in diverse communities and settings. Our study revealed the following key themes: (1) attention must be paid to gender and power dynamics in ATI trials; (2) ATI trials should be designed and implemented through the lenses of intersectionality and equity frameworks; (3) ATI trials may have both positive and negative effects on stigma for PLWH and their partners; and (4) partnership dynamics should be considered when designing ATI protocols. Our study generated actionable considerations that could be implemented in ATI trials to promote their acceptability to communities that have been underrepresented in HIV cure research to date. Research teams must invest in robust community and stakeholder engagement to define best practices. Paying attention to representation and equity will also promote better and more equitable implementation of HIV cure strategies once these become ready for rollout.

Entities:  

Keywords:  HIV; HIV cure research; analytical treatment interruption; minorities; partner protection; people living with HIV; race and ethnicity; transgender women; women

Mesh:

Year:  2021        PMID: 33947268      PMCID: PMC8785755          DOI: 10.1089/AID.2021.0023

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  55 in total

1.  The Pre-Exposure Prophylaxis Cascade in At-Risk Transgender Men Who Have Sex with Men in the United States.

Authors:  Sari L Reisner; Chiara S Moore; Andrew Asquith; Dana J Pardee; Kenneth H Mayer
Journal:  LGBT Health       Date:  2021-02-09       Impact factor: 4.151

2.  A Gap Between Willingness and Uptake: Findings From Mixed Methods Research on HIV Prevention Among Black and Latina Transgender Women.

Authors:  Tonia Poteat; Andrea Wirtz; Mannat Malik; Erin Cooney; Christopher Cannon; W David Hardy; Renata Arrington-Sanders; Maren Lujan; Thespina Yamanis
Journal:  J Acquir Immune Defic Syndr       Date:  2019-10-01       Impact factor: 3.731

Review 3.  The syndemic illness of HIV and trauma: implications for a trauma-informed model of care.

Authors:  Christina Brezing; Maria Ferrara; Oliver Freudenreich
Journal:  Psychosomatics       Date:  2014-10-08       Impact factor: 2.386

4.  Minorities remain underrepresented in HIV/AIDS research despite access to clinical trials.

Authors:  Jose R Castillo-Mancilla; Susan E Cohn; Supriya Krishnan; Michelle Cespedes; Michelle Floris-Moore; Gail Schulte; Gregory Pavlov; Donna Mildvan; Kimberly Y Smith
Journal:  HIV Clin Trials       Date:  2014 Jan-Feb

Review 5.  Barriers to a cure for HIV in women.

Authors:  Sara Gianella; Athe Tsibris; Liz Barr; Catherine Godfrey
Journal:  J Int AIDS Soc       Date:  2016-02-18       Impact factor: 5.396

6.  Willingness to participate and take risks in HIV cure research: survey results from 400 people living with HIV in the US.

Authors:  Karine Dubé; David Evans; Laurie Sylla; Jeff Taylor; Bryan J Weiner; Asheley Skinner; Harsha Thirumurthy; Joseph D Tucker; Stuart Rennie; Sandra B Greene
Journal:  J Virus Erad       Date:  2017-01-01

7.  How to Address the Risk of HIV Transmission in Remission Studies With Treatment Interruption: The Low-Hanging Fruit Approach.

Authors:  Nir Eyal
Journal:  J Infect Dis       Date:  2019-07-02       Impact factor: 5.226

8.  Stakeholder engagement to inform HIV clinical trials: a systematic review of the evidence.

Authors:  Suzanne Day; Meredith Blumberg; Thi Vu; Yang Zhao; Stuart Rennie; Joseph D Tucker
Journal:  J Int AIDS Soc       Date:  2018-10       Impact factor: 5.396

9.  Effective Engagement Requires Trust and Being Trustworthy.

Authors:  Consuelo H Wilkins
Journal:  Med Care       Date:  2018-10       Impact factor: 2.983

Review 10.  Applying the Behavioural and Social Sciences Research (BSSR) Functional Framework to HIV Cure Research.

Authors:  Karine Dubé; Judith D Auerbach; Michael J Stirratt; Paul Gaist
Journal:  J Int AIDS Soc       Date:  2019-10       Impact factor: 5.396

View more
  9 in total

Review 1.  Short Communication: Population Representation in HIV Cure Research: A Review of Diversity Within HIV Cure Studies Based in the United States.

Authors:  Carly Roberts; Emma Creamer; Cheriko A Boone; A Toni Young; Manya Magnus
Journal:  AIDS Res Hum Retroviruses       Date:  2022-02-21       Impact factor: 1.723

2.  Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP).

Authors:  Michelle Cespedes; Moupali Das; J Carlo Hojilla; Jill Blumenthal; Karam Mounzer; Moti Ramgopal; Theo Hodge; Thiago S Torres; Charles Peterson; Senzokuhle Shibase; Ayana Elliott; A C Demidont; Larkin Callaghan; C Chauncey Watson; Christoph Carter; Alex Kintu; Jared M Baeten; Onyema Ogbuagu
Journal:  PLoS One       Date:  2022-06-03       Impact factor: 3.752

3.  The ethical imperative to reduce HIV stigma through community-engaged, status-neutral interventions designed with and for transgender women of colour in the United States.

Authors:  Kristi E Gamarel; Greg Rebchook; Breonna M McCree; Laura Jadwin-Cakmak; Maureen Connolly; Lilianna A Reyes; Jae M Sevelius
Journal:  J Int AIDS Soc       Date:  2022-07       Impact factor: 6.707

4.  Preliminary Acceptability of a Home-Based Peripheral Blood Collection Device for Viral Load Testing in the Context of Analytical Treatment Interruptions in HIV Cure Trials: Results from a Nationwide Survey in the United States.

Authors:  Karine Dubé; Shadi Eskaf; Elizabeth Hastie; Harsh Agarwal; Laney Henley; Christopher Roebuck; William B Carter; Lynda Dee; Jeff Taylor; Derrick Mapp; Danielle M Campbell; Thomas J Villa; Beth Peterson; Kenneth M Lynn; Linden Lalley-Chareczko; Emily Hiserodt; Sukyung Kim; Daniel Rosenbloom; Brad R Evans; Melanie Anderson; Daria J Hazuda; Lisa Shipley; Kevin Bateman; Bonnie J Howell; Karam Mounzer; Pablo Tebas; Luis J Montaner
Journal:  J Pers Med       Date:  2022-02-07

5.  Bringing social context into global biomedical HIV cure-related research: An urgent call to action.

Authors:  Annie Miall; Rio McLellan; Krista Dong; Thumbi Ndung'u; Parya Saberi; John A Sauceda; Karine Dubé
Journal:  J Virus Erad       Date:  2021-12-28

6.  Ethical and practical considerations for cell and gene therapy toward an HIV cure: findings from a qualitative in-depth interview study in the United States.

Authors:  Karine Dubé; John Kanazawa; Hursch Patel; Michael Louella; Laurie Sylla; Jeff Sheehy; Lynda Dee; Jeff Taylor; Jen Adair; Kim Anthony-Gonda; Boro Dropulić; John A Sauceda; Michael J Peluso; Steven G Deeks; Jane Simoni
Journal:  BMC Med Ethics       Date:  2022-04-09       Impact factor: 2.834

7.  "It comes altogether as one:" perceptions of analytical treatment interruptions and partner protections among racial, ethnic, sex and gender diverse HIV serodifferent couples in the United States.

Authors:  Danielle M Campbell; Karine Dubé; Portia D Cowlings; Patricia Dionicio; Rowena M Tam; Harsh Agarwal; Jamila K Stockman; Judith D Auerbach; John A Sauceda; Amy A Conroy; Mallory O Johnson
Journal:  BMC Public Health       Date:  2022-07-09       Impact factor: 4.135

8.  Perceptions of HIV cure and willingness to participate in HIV cure-related trials among people enrolled in the Netherlands cohort study on acute HIV infection.

Authors:  Pien van Paassen; Maartje Dijkstra; Holly L Peay; Casper Rokx; Annelies Verbon; Peter Reiss; Jan M Prins; Gail E Henderson; Stuart Rennie; Pythia T Nieuwkerk; Godelieve J de Bree
Journal:  J Virus Erad       Date:  2022-06-15

Review 9.  Ethics of HIV cure research: an unfinished agenda.

Authors:  Karine Dubé; John Kanazawa; Jeff Taylor; Lynda Dee; Nora Jones; Christopher Roebuck; Laurie Sylla; Michael Louella; Jan Kosmyna; David Kelly; Orbit Clanton; David Palm; Danielle M Campbell; Morénike Giwa Onaiwu; Hursch Patel; Samuel Ndukwe; Laney Henley; Mallory O Johnson; Parya Saberi; Brandon Brown; John A Sauceda; Jeremy Sugarman
Journal:  BMC Med Ethics       Date:  2021-06-30       Impact factor: 2.834

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.